We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




IV Solution Treats Surgical Blood Volume Loss

By HospiMedica staff writers
Posted on 08 Jan 2008
An intravenous starch solution prevents and treats dangerous loss of blood volume, a condition that sometimes occurs during and after surgery. More...


Voluven, a synthetic starch (6% hydroxyethyl starch) solution that does not dissolve in water, is formed by linked individual starch molecules combined with normal saline (0.9% sodium chloride); the starch solution works by expanding blood volume, restoring some of the blood volume lost during surgery. The starch-enriched plasma draws fluid into the capillaries so that remaining red blood cells can continue to deliver oxygen to the body's tissues.

In clinical trials, Voluven was compared to other approved blood volume expanders. In newborns and infants undergoing major surgery, it was found as safe and effective as an equivalent volume of another approved starch solution expander containing albumin, Hespan, manufactured by B. Braun Medical (Bethlehem, PA, USA). In other trials conducted outside of the United States, Voluven was as safe as other blood volume expanders used in those countries in patients ranging in age from less than two years to 75 years who were undergoing a variety of surgical procedures.

Voluven is not recommended for patients with known abnormal sensitivity to the synthetic starch used in the product; patients experiencing fluid overload; patients with kidney failure not related to low blood volume; patients on dialysis; patients with severe increases in blood levels of sodium or chloride; and patients with intracranial bleeding. Voluven is manufactured by Fresenius Kabi (Bad Homburg, Germany), and has been approved by the U.S. Food and Drug Administration (FDA).

"Massive blood loss is a life-threatening problem. Approval of Voluven provides clinicians with an alternative blood volume product that is safe and effective in a wide range of age groups,” said Jesse L. Goodman, M.D., M.P.H., director of FDA's Center for biologics evaluation and research.


Related Links:
Fresenius Kabi
B. Braun Medical

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
LED Surgical Lamp
ACEMST35/57
IV Therapy Cart
Avalo I.V Therapy Cart
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.